Skip to main content

Physician payments & other transfers
of value

We’re guided by openness and transparency in our relationships with health care providers (HCPs), health care organizations (HCOs) and patient organizations.

We believe interactions with health care professionals bring value to patient care

AbbVie is committed to collaborating with health care professionals (HCPs), health care organizations (HCOs) and patient organizations to improve patient health across the globe. Our interactions with HCPs, HCOs and patient organizations are guided by openness and transparency to ensure public trust and confidence. AbbVie supports disclosure of these relationships wherever possible to demonstrate the integrity of our relationships with HCPs, HCOs and patient organizations.

HCP/HCO disclosures inside the US

Open payments—Physician Payments Sunshine Act

The US Sunshine Act, also known as the Open Payments—Physician Payments Sunshine Act, was enacted as federal law in 2010 as a component of the Affordable Care Act. The Act requires health care manufacturers, including AbbVie, to track financial transactions with certain health care providers (HCPs) and health care organizations (HCOs) and to disclose those transactions on an annual basis. We support the Act and its goal of providing the public greater visibility into interactions between the health care industry and HCPs to ensure public trust and confidence. To learn more,  view our FAQs.

U.S. Centers for Medicare and Medicaid Services (CMS) Open Payments Website

If you have questions on the data contained in the reports, please email TransparencyReporting@abbvie.com.

Allergan acquisition

On May 8, 2020, AbbVie completed its acquisition of Allergan, which is now part of AbbVie. To access Allergan’s payments and transfers of value submitted to CMS, please visit: openpaymentsdata.cms.gov.

To access Allergan HCP / HCO disclosures outside of the US please visit: Click here.

AbbVie HCP/HCO disclosures outside of the US

Information exchanged with Healthcare Professionals (HCPs), Healthcare Organizations (HCOs) and patient organizations leads to newer and better therapies and, most importantly, enhanced care for patients. We believe interactions with healthcare professionals and healthcare organizations are essential to advance patient care, gain insights into unmet medical needs and progress the development of new medicines. Our interactions with HCPs and HCOs are based on trust, transparency and integrity, with a goal of providing the public with greater visibility into these interactions to ensure public trust and confidence. AbbVie engages in a range of activities from clinical research to sponsorships to educational activities to exchange information on how new medicines fit into the patient pathway. By bringing greater transparency to these relationships, AbbVie demonstrates its ongoing commitment to strengthening the basis for future collaboration.

Asia Pacific

Australia
Disclosure data

Japan
Disclosure data

New Zealand
Disclosure Data

Republic of Korea - Data available upon request by the Ministry of Health and Welfare, an HCP or HCO

Europe

Transparency throughout our industry is a cornerstone of the pact of trust we have with patients and society. As such, AbbVie is proud to disclose our data on transfers of value to HCPs and HCOs in Europe in accordance with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code, national laws and regulations and country-specific industry codes. In addition, AbbVie has annually published data regarding the financial support we provide to European Patient Organizations since 2010.

Austria
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Belgium
2019 – Disclosure Data
2020 – Disclosure Data
2021 – Disclosure Data

Bosnia & Herzegovina
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Bulgaria
2018 – Disclosure ReportAdditional Document
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Croatia
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Cyprus
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – No Transfers of Value, Additional Document

Czech Republic
2019 – AIFP Disclosure DataAIFP Congress Sponsoring
2020 – AIFP Disclosure DataAIFP Congress Sponsoring
2021 – AIFP Disclosure DataAIFP Congress Sponsoring

Estonia
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Finland
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

France
2019 - Disclosure Data
2020 - Disclosure Data
2021 - Disclosure Data

Germany
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Greece
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Hungary
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Iceland  
2019 – Disclosure Data
2020 – Disclosure Data - No Transfers of Value
2021 – Disclosure Data - No Transfers of Value

Ireland
2019 – Disclosure Data
2020 – Disclosure Data 
2021 – Disclosure Data

Italy
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Latvia
2019 – Disclosure ReportAdditional Document
2020 – Disclosure DataAdditional Document
2021 – Disclosure DataAdditional Document

Lithuania
2019 – Disclosure ReportAdditional Document
2020 – VVKT Disclosure Data
2020 – IFPA Disclosure ReportAdditional Document
2021 – VVKT Disclosure Data
2021 – IFPA Disclosure ReportAdditional Document

Luxembourg
2019 – Disclosure ReportAdditional Document
2020 – Disclosure Report, Additional Document
2021 – Disclosure Report, Additional Document

Malta
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Netherlands
2019 – Disclosure Data
2020 – Disclosure Data
2021 – Disclosure Data

Norway
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Poland
2019 – Disclosure ReportAdditional Document
2020 – Disclosure Report,  Additional Document
2021 – Disclosure Report,  Additional Document

Portugal
Disclosure Data*

*Please use Google Chrome to view this link.

Republic of North Macedonia
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – No Transfers of Value, Additional Document

Romania
2019 – Disclosure Data
2020 – Disclosure Data
2021 – Disclosure Data

Russia
2019 – Disclosure Data
2020 – Disclosure Data
2021 – Disclosure Data

Serbia
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Slovakia
2019 – MoH Disclosure Data
2019 – AIFP Disclosure Report, AIFP Additional Document
2020 – MoH Disclosure Data
2020 – AIFP Disclosure Report, AIFP Additional Document
2021 – MoH Disclosure Data
2021 – AIFP Disclosure Report, AIFP Additional Document
2022 – MoH Disclosure Data

Slovenia
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Spain
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Sweden
2019 – Disclosure Data
2020 – Disclosure Data
2021 – Disclosure Data

Switzerland
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

Turkey – Data submitted per Ministry of Health requirement

Ukraine
2019 – Disclosure ReportAdditional Document
2020 – Disclosure ReportAdditional Document
2021 – Disclosure ReportAdditional Document

United Kingdom
2019 – ABPI Disclosure Data
2020 – ABPI Disclosure Data
2021 – ABPI Disclosure Data

EFPIA Disclosure Code—2020 Self-Certification Scheme

EFPIA Disclosure Code—2021 Self-Certification Scheme

EFPIA Disclosure Code—2022 Self-Certification Scheme

Latin America

Brazil (Minas Gerais) -  Disclosure Data

Colombia - Data submitted per Ministry of Health requirement

Mexico - Data submitted per Trade Association request

Middle East/Africa

Saudi Arabia - Data submitted per the Saudi Food and Drug Authority requirement

European patient organization relationships

AbbVie is committed to making a remarkable impact on patients’ lives and their caregivers.  We combine advanced science with a deep knowledge of the patient experience and healthcare systems to help people live better, more productive lives. We pursue learning about patient experiences to understand the issues, concerns and priorities of people affected by disease.

Patient organizations are a source of valuable information and support for patients and their caregivers. We foster patient organization relationships based on mutual trust, respect and goals that reflect AbbVie’s transparent and ethical behavioral standards. Through these relationships, AbbVie contributes to informing patients and caregivers about disease states, treatment options and how to improve quality of life. These partnerships facilitate dialogue between interested parties and help create new, cost-effective health care delivery models.

Annually, AbbVie publishes a list of its financial support of European Patient Organizations. Our publication of the following report demonstrates our commitment to transparent disclosure of our financial relationships with patient organizations.

AbbVie’s 2021 European Patient Organization ReportAdditional Document

*Please note that the report includes support values for Belgium, France, Netherlands, Romania, Portugal and Turkey, which are also disclosed as part of their local Transparency legislation.

Serbia – Sponsored Professional Conferences

AbbVie has a long-standing commitment to supporting programs aimed at increasing the understanding of scientific, clinical and health care issues that improve patient care. In the interest of transparency, we are disclosing the following list of professional conferences sponsored by AbbVie.

Sponsored Professional Conferences 2013
Sponsored Professional Conferences 2014
Sponsored Professional Conferences 2015
Sponsored Professional Conferences 2016
Sponsored Professional Conferences 2017
Sponsored Professional Conferences 2018
Sponsored Professional Conferences 2019
Sponsored Professional Conferences 2020